An Italian direct-to-consumer supplements brand, involved in microorganism-based formulations for gut-health, offers a range of 17 products for humans and pets. Operating on its own e-commerce platform, the business reports approximately EUR 284,110 in revenue and EUR 145,693 in net profit between November 2025 and October 2026, with a significant profit margin. FY 2025 reported EUR 477,776 in revenue and EUR 273,821 in net profit. The enterprise leverages unpaid channels such as returning customers and social media, with minimal spending on Meta Ads. Operational expenses include staff costs, COGS, shipping, and various smaller costs. In recent financial trends, a slowdown in 2026 attributed to reduced staff activity impacted sales, but the business saw significant growth in 2025. Sales processes include customer registration via WooCommerce and a partner training course. Assets offered for sale include the brand’s domain, product range, website content, social media accounts, customer database, and supplier relationships. Growth opportunities range from increased paid advertising to expanding market presence in the EU and developing the pet product line. The ideal buyer is someone with expertise in health supplements or an operator looking to revitalize the brand post-2026 slowdown. Essential due diligence focuses on trademarks, formulas, and regulatory status. Prospective buyers are encouraged to reach out, sign an NDA, and engage with the broker for more details. This acquisition targets those looking for a brand with a defined niche, a substantial product catalog, and robust financial data over several years, complemented by growth potential.